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ABSTRACT
Background: Observed associations of high-protein diets with
changes in insulin resistance are inconclusive.
Objectives: We aimed to assess associations of changes in both
reported and estimated protein (PRep; PEst) and energy intake
(EIRep; EIEst) with changes in HOMA-IR, glycated hemoglobin
(HbA1c), and BMI (in kg/m2), in 1822 decreasing to 833 adults
(week 156) with overweight and prediabetes, during the 3-y
PREVIEW (PREVention of diabetes through lifestyle intervention
and population studies In Europe and around the World) study on
weight-loss maintenance. Eating behavior and measurement errors
(MEs) of dietary intake were assessed. Thus, observational post hoc
analyses were applied.
Methods: Associations of changes in EIEst, EIRep, PEst, and PRep
with changes in HOMA-IR, HbA1c, and BMI were determined by
linear mixed-model analysis in 2 arms [high-protein-low-glycemic-
index (GI) diet and moderate-protein-moderate-GI diet] of the
PREVIEW study. EIEst was derived from energy requirement: total
energy expenditure = basal metabolic rate × physical activity
level; PEst from urinary nitrogen, and urea. MEs were calculated as
[(EIEst − EIRep)/EIEst] × 100% and [(PRep − PEst)/PEst] × 100%.
Eating behavior was determined using the Three Factor Eating
Questionnaire, examining cognitive dietary restraint, disinhibition,
and hunger.
Results: Increases in PEst and PRep and decreases in EIEst and EIRep
were associated with decreases in BMI, but not independently with
decreases in HOMA-IR. Increases in PEst and PRep were associated
with decreases in HbA1c. PRep and EIRep showed larger changes and
stronger associations than PEst and EIEst. Mean ± SD MEs of EIRep
and PRep were 38% ± 9% and 14% ± 4%, respectively; ME changes
in EIRep and En% PRep were positively associated with changes in
BMI and cognitive dietary restraint and inversely with disinhibition
and hunger.
Conclusions: During weight-loss maintenance in adults with
prediabetes, increase in protein intake and decrease in energy
intake were not associated with decrease in HOMA-IR beyond
associations with decrease in BMI. Increases in PEst and PRep
were associated with decrease in HbA1c. This trial was regis-
tered at clinicaltrials.gov as NCT01777893. Am J Clin Nutr
2021;114:1847–1858.
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Introduction
The global increase in the rate of type 2 diabetes (T2D),
mainly due to overweight and obesity, calls for prevention
of T2D in predisposed individuals (1). The primary factor in
remission and prevention is body-weight loss, as was shown
by the DiRECT (Diabetes Remission Clinical Trial) study (2,
3). In addition, the 3-y PREVIEW (PREVention of diabetes
through lifestyle intervention and population studies In Europe
and around the world) study showed that reduction in insulin
resistance, expressed as HOMA-IR, was associated with weight-
loss maintenance (4). Previous diabetes prevention lifestyle
intervention studies including energy-restriction diets for weight-
loss maintenance, possibly together with physical activity (PA)
programs, have found reductions in the incidence of T2D
Supported by European Union (EU) framework programme 7 (FP7/2007-
2013) grant agreement #312057 (to AR); National Health and Medical
Research Council–EU collaborative grant, AUS 8, ID 1067711 (to JB-M);
the Glycemic Index Foundation Australia through royalties to The University
of Sydney (to JB-M); NZ Health Research Council grant 14/191 and the
University of Auckland Faculty Research Development Fund (to SDP); the
Danish Agriculture & Food Council (to AR); the Danish Meat and Research
Institute (to AR); the National Institute for Health Research Biomedical
Research Centre (to IAM); the Biotechnology and Biological Sciences
Research Council (to IAM); the Engineering and Physical Sciences Research
Council (to IAM); the Juho Vainio Foundation (to EJ); Academy of Finland
grants 272376, 314383, 266286, and 314135 (to KHP); the Finnish Medical
Foundation (to KHP); the Gyllenberg Foundation (to KHP); the Novo Nordisk
Foundation (to AR); the Finnish Diabetes Research Foundation (to KHP);
University of Helsinki (to KHP); Government Research Funds for Helsinki
University Hospital (to KHP); the Jenny and Antti Wihuri Foundation (to
KHP); and the Emil Aaltonen Foundation (to KHP). The Cambridge Weight
Plan© donated all products for the 8-wk low-energy diet period (to AR).
Nutritics (Dublin) donated all dietary analysis software used by the University
of Nottingham (to IAM).
The funding source only granted the project and approved the successive
reports including the final report. The funding source was not involved in the
study design; collection, analyses, and interpretation of data; nor in writing
the manuscript; nor in the decision to submit the paper for publication.
Address correspondence to MSW-P (e-mail: m.westerterp@
maastrichtuniversity.nl).
Abbreviations used: AlcRep, reported alcohol intake; BMR, basal metabolic
rate; CHO, carbohydrate; EE, energy expenditure; EI, energy intake;
EIEst, estimated energy intake; EIRep, reported energy intake; En%, energy
percentage; F, fat; FFM, fat-free mass; FM, fat mass; F1, Factor 1 (cognitive
dietary restraint); F2, Factor 2 (disinhibition and emotional eating); F3,
Factor 3 (hunger); GI, glycemic index; GL, glycemic load; HbA1c, glycated
hemoglobin; HP, high-protein, low-glycemic-index diet; ME, measurement
error; MP, moderate-protein, moderate-glycemic-index diet; P, protein; PA,
physical activity; PAL, Physical Activity Level; PEst, estimated protein intake;
PRep, reported protein intake; PREVIEW, PREVention of diabetes through
lifestyle intervention and population studies In Europe and around the World;
RCT, randomized controlled trial; TEE, total energy expenditure; TFEQ,
Three Factor Eating Questionnaire; T2D, type 2 diabetes.
Received January 4, 2021. Accepted for publication June 30, 2021.
First published online August 10, 2021; doi: https://doi.org/10.1093/ajcn/
nqab247.
using low-fat, high-carbohydrate (CHO), high-fiber energy-
restricted diets (5–7). The PREVIEW study hypothesized that a
relatively high-protein, low-glycemic-index (GI) diet (hereafter
HP) would support weight-loss maintenance to a greater extent
and concurrently reduce insulin resistance. This study compared
HP with a moderate-protein, moderate-GI diet (hereafter MP)
for body-weight reduction and concurrent prevention of T2D (4,
8–15). However, despite the differences in dietary instructions,
both the HP and MP groups achieved considerable and similar
weight-loss maintenance, reduced HOMA-IR, and reduced
glycated hemoglobin (HbA1c), a measure of average blood
glucose concentration (4). None of the aforementioned lifestyle
intervention studies analyzed the independent effects of the diets
on HOMA-IR and HbA1c, independently of their effects on
weight-loss maintenance (4–8). The present study addresses the
question of whether an increase in protein (P) intake and decrease
in energy intake (EI) may independently be associated with a
decrease in HOMA-IR and HbA1c, as a post hoc analysis of the
PREVIEW study. Previous reports on this topic are inconclusive
(15–20). In the Lifelines study, a P score indicating total energy
percentage (En%) P, plus the ratio of plant to animal P, was
independently inversely associated with HbA1c (16). Moreover,
plant and egg P seemed to decrease (17), whereas reported
animal P seemed to increase, T2D risk (18, 19). However, the
self-reported diets carry the risk of measurement error (ME),
as shown by a concordance of self-reported P with a urinary
biomarker of only 48% (16). MEs may be due to error in
reporting, the measurement tool, or the nutrient database, which
may lead to incorrect conclusions (21–29). However, total EI
and P intake can be estimated based upon measured parameters
such as those collected during the PREVIEW study (8, 26–32).
In the current post hoc analysis, we investigated associations of
changes in reported and estimated P (PRep; PEst) and EI (EIRep;
EIEst) with changes in HOMA-IR, HbA1c, and BMI (in kg/m2)
during weight-loss maintenance after 8 wk weight loss. MEs were
determined, and possible associations of changes in MEs with
changes in HOMA-IR, HbA1c, and BMI investigated. Because
weight-loss maintenance has also been shown to be associated
with changes in cognitive dietary restraint, disinhibition, and
hunger (10, 11, 33–35), these factors were included in the present
analysis.
Methods
PREVIEW lifestyle intervention study protocol
The design (8) and main results (4) of the PREVIEW
study (NCT01777893) have been published previously. In short,
the PREVIEW lifestyle intervention study was a multicenter
randomized controlled trial (RCT) aimed at finding an effective
lifestyle intervention to prevent the development of T2D in
2326 individuals with prediabetes as defined by the American
Diabetes Association criteria (8): fasting plasma glucose 5.6–
6.9 mmol/L and/or 7.8–11.0 mmol/L at 2 h after an oral-
glucose-tolerance test of 75 g glucose, with a fasting plasma
glucose concentration <7.0 mmol/L. Inclusion and exclusion
criteria have been described before (8). The study consisted of
2 phases: an 8-wk weight loss period using a low-energy diet,
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Assessed for eligibility (n = 5472)• Enrollment
Excluded (n = 3249)
¨ Not meeting inclusion criteria (n = 3146)
¨ Declined to participate (n = 103)
Individuals starting Baseline and weight-loss phase with LED                                                  
Randomly assigned (n = 2223)
Randomly assigned to MP-MI and MP-HI, together MP (n = 1112)
Attended week 0; sufficient data n = 899
Randomly assigned to HP-MI and HP-HI (n = 1111)
Aended week 0; sufficient data n = 923
8-wk weight-loss phase
Attended 26 wk  n = 805                                                       
Sufficient data n = 648
Attended 26 wk n = 822                                                       
Sufficient data n = 644
26 wk
Attended 52 wk  n = 671                                                       
Sufficient data n = 551
Attended 104 wk  n = 542                                                       
Sufficient data n = 439
Attended 156 wk  n = 472                                                      




Attended 52 wk n = 710                                                       
Sufficient data n = 528
Attended 104 wk n = 551                                                       
Sufficient data n = 450
Attended 156 wk n = 473                                                       
Sufficient data n = 413
FIGURE 1 Participant flowchart. Numbers of participants in the HP and MP groups. Data used for the present analysis are indicated by “sufficient data,”
including complete data on BMI, body composition, HOMA-IR, glycated hemoglobin, 4-d food diaries, urinary nitrogen, and accelerometry. HI, high-intensity;
HP, high-protein, low-glycemic-index diet; LED, low-energy diet; MI, moderate-intensity; MP, moderate-protein, moderate-glycemic-index diet.
by a 148-wk weight-maintenance period with instructions to
follow the guidelines of 1 of the 4 intervention groups: MP
or HP, combined with either moderate- or high-intensity PA
(8). The primary endpoint was 3-y incidence of T2D analyzed
by diet treatment. Secondary outcomes included HOMA-IR,
HbA1c, and body weight (8). In the main study, a conservative
estimate of sample size was 649/group or 1298 participants in
total (2-sided comparison, power = 80%, α = 0.05), based
upon a risk reduction of 50% in the HP and 25% in the MP
group. With 30% dropout, 1854 subjects should have started the
weight-maintenance phase (4). A secondary power calculation
for HbA1c anticipated a difference between the 2 diet groups of
0.2% points (SD = 0.6% points). Using an 80% power and α of
0.05, the estimated sample size for each group was 142. Allowing
for 30% dropout, the sample size required was 205/group
(4). The study protocol and amendments were reviewed and
approved by the local Human Ethics Committee at each of the
8 intervention centers. The work of the PREVIEW study was
carried out in full compliance with the relevant requirements of
the latest version of the Declaration of Helsinki (59th World
Medical Association General Assembly, Seoul, Republic of
Korea, October 2008) and The International Conference on
Harmonisation for Good Clinical Practice, to the extent possible
and relevant. All participants provided written informed consent
before any screening procedures. All information obtained during
the trial was handled according to the local regulations and
European Directive 95/46/CE (the directive on protection of
individuals with regard to the processing of personal data and on
the free movement of such data). Recruitment of participants for
the 3-y study started in 2013; the first clinical investigation day
(week 0) was in 2014; the last participants had their final clinical
investigation days (week 156) in 2018.
The methods used to measure body weight, height, and body
composition, blood sampling, and analyses have been described
previously (4, 8).
HOMA-IR appeared to be significantly reduced by 38% after
weight loss, and by 16% after weight maintenance, in the
completers (4). The primary outcome, i.e., total number of T2D
cases, was 62 and the cumulative incidence rate was 3.1%,
with no significant differences between the 2 diets, PA, or their
combination (4). T2D incidence was similar across intervention
centers, irrespective of attrition. There were no group differences
in body weight change (−11% after 8 wk weight reduction; −5%
after 3 y weight maintenance) or in other secondary outcomes
(4). It was concluded that the 3-y incidence of T2D was much
lower than predicted and did not differ between diets, PA, or
their combination. The overall protocol combining weight loss,
healthy eating, and PA was successful in markedly reducing the
risk of T2D (4).
The 1822 PREVIEW study participants included in the
present post hoc analyses were those with completed 4-d food
intake diaries, urine collection, and accelerometry at the clinical
investigation days at baseline (week 0), and throughout the
weight-maintenance phase at 26, 52, 104, and 156 wk (Figure 1,
Table 1).
Reported dietary intake
Dietary intake was reported using 4-d dietary intake diaries
including weekdays and weekend days, at baseline (week 0),
and during the weight-maintenance phase at 26, 52, 104, and
156 wk. Consumption of all foods and drinks on those 4 d had
to be recorded both quantitatively (the amount) and qualitatively
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TABLE 1 Participant characteristics at baseline (week 0) and during the intervention in the HP and MP groups1
Characteristic Group Week 0 Week 26 Week 52 Week 104 Week 156
n (female/male) HP 923 (618/305) 644 (429/215) 528 (352/176) 450 (288/162) 413§ (271/142)
MP 899 (594/305) 648 (428/220) 551 (354/197) 439 (273/166) 420§ (271/149)
Age HP 51.7 ± 11.6 — — — —
MP 51.4 ± 11.5 — — — —
BMI, kg/m2 HP 35.4 ± 6.6 30.8 ± 5.5§ 31.1 ± 5.5§ 31.3 ± 5.4§ 31.6 ± 5.3§
MP 35.5 ± 6.6 30.6 ± 5.5§ 31.1 ± 5.9§ 31.6 ± 5.7§ 32.0 ± 6.0§
Body fat, % HP 43.2 ± 7.5 37.2 ± 8.9§ 37.7 ± 8.9§ 38.6 ± 8.8§ 39.6 ± 8.6§
MP 43.4 ± 7.6 37.5 ± 8.8§ 38.3 ± 9.1§ 39.2 ± 9.0§ 40.5 ± 8.9§
BMR, MJ/d HP 7.6 ± 1.4 7.2 ± 1.2§ 7.2 ± 1.2§ 7.2 ± 1.2§ 7.2 ± 1.2§
MP 7.7 ± 1.4 7.2 ± 1.2§ 7.2 ± 1.3§ 7.3 ± 1.3§ 7.3 ± 1.3§
PAL HP 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1
MP 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1
HOMA-IR HP 3.8 ± 2.6 2.3 ± 1.3§ 2.5 ± 1.4§ 2.7 ± 1.7§ 2.8 ± 1.8§
MP 3.7 ± 2.4 2.2 ± 1.3§ 2.4 ± 1.6§ 2.6 ± 1.5§ 2.8 ± 1.9§
HbA1c, mmol/mol HP 36.7 ± 3.9 34.9 ± 3.0§ 35.4 ± 3.1§ 36.4 ± 3.6 36.3 ± 3.4
MP 36.7 ± 4.1 34.8 ± 3.2§ 35.5 ± 3.6§ 36.0 ± 3.8 36.5 ± 3.8
HbA1c, % HP 5.5 ± 0.4 5.3 ± 0.3§ 5.4 ± 0.3 5.5 ± 0.3 5.5 ± 0.3
MP 5.5 ± 0.4 5.3 ± 0.3§ 5.4 ± 0.3 5.4 ± 0.3 5.5 ± 0.3
TFEQ F1 HP 7.9 ± 4.0 13.6 ± 3.6§ 13.2 ± 3.7§ 12.5 ± 4.1§ 12.3 ± 4.0§
MP 8.0 ± 4.3 13.6 ± 3.8§ 13.2 ± 4.0§ 12.7 ± 4.2§ 12.3 ± 4.3§
TFEQ F2 HP 9.2 ± 3.5 7.3 ± 3.5§ 7.6 ± 3.6§ 7.8 ± 3.6§ 7.7 ± 3.6§
MP 9.0 ± 3.5 7.4 ± 3.4§ 7.7 ± 3.6§ 7.8 ± 3.7§ 7.9 ± 3.8§
TFEQ F3 HP 7.0 ± 3.6 4.9 ± 3.5§ 5.3 ± 3.7§ 5.5 ± 3.7§ 5.5 ± 3.8§
MP 7.0 ± 3.5 5.1 ± 3.5§ 5.4 ± 3.6§ 5.4 ± 3.7§ 5.4 ± 3.8§
1Values are means ± SDs. Linear mixed-model analyses adjusting for age, sex, study center, and BMI were used to assess differences between the
intervention groups. None were observed. BMR, basal metabolic rate; F1, cognitive dietary restraint; F2, disinhibition; F3, hunger; HbA1c, glycated
hemoglobin; HP, high-protein, low-GI diet; MP, moderate-protein, moderate-GI diet; PAL, Physical Activity Level; TFEQ, Three Factor Eating Questionnaire.
§Statistically significant difference from week 0 (P < 0.01).
clinical investigation days at baseline and 26, 52, 104, and
156 wk, and were checked by the researcher together with the
participant. Reported dietary intake data were analyzed using
national food tables for each country. If available, national GI data
for the GIs of food items were used; if not, the Australian GI data
were used (36). Analyses of reported dietary intake provided total
EI (EIRep), macronutrient composition, GI, and glycemic load
(GL) (4, 10). The means of these data over 4 d were calculated and
reported for the 1822 participants in the present study (Table 2).
These reports of EI and P intake were used in the present analyses.
Estimated dietary intake
At 0, 26, 52, 104, and 156 wk EI was estimated (EIEst), based
upon energy requirement determined by total energy expenditure
(TEE): TEE = basal metabolic rate (BMR) × Physical Activity
Level (PAL) (26–29, 32). During diet- and PA-induced weight
loss and subsequent weight maintenance, body mass, fat mass
(FM), fat-free mass (FFM), and PA will change. Consequently
TEE, including BMR, changes during that period of time.
Therefore, we applied a model using existing knowledge on the
relation between EI, FFM, and FM, and EE in energy balance as
well as at changing energy balance (32). The adaptation of BMR
to a changing diet, a changing activity budget, and to resulting
changes in FM and FFM was included (32). Under these dynamic
conditions, BMR was calculated based upon measured FFM and
FM at each time point, i.e., on the clinical investigation days in
weeks 0, 26, 52, 104, and 156. Body composition was determined
using DXA, BodPod, or bioimpedance, yielding FFM and FM (4,
8). Thus BMR was calculated as BMR (MJ/d) = 0.102FFM (kg)
+ 0.024FM (kg) + 0.85 (32). Also, at each of these time points,
PAL was calculated based upon the accelerometer outputs (4, 8,
37–40). For activity-induced energy expenditure, the ActiSleep+
(ActiGraph LLC) accelerometer was worn. It was attached to an
elastic waist belt worn over the right mid-axillary line 24 h/d
for 7 consecutive days before the clinical investigation day, and
removed only for water-based activities. Counts per minute were
derived and used to estimate PA (4, 8). The ActiSleep+ has
previously been validated with doubly labeled water–assessed
TEE (36–39). PAL was estimated using accelerometer counts,
with the following equation: PAL = 0.0005882 counts/min
daily + 1.45 (39, 40). EIRep was compared with EIEst, yielding
the relative ME of EIRep, calculated as [(EIEst − EIRep)/EIEst] ×
100%.
P intake was estimated (PEst) based upon urinary nitrogen
(4, 8, 30, 31) or urea (4, 8), collected during a day just before
the clinical investigation day. Urine collection was ensured by a
standard operating procedure as well as an instruction material
and tools for the participants. A urine collection <0.5 L/d was
regarded as incomplete. The participants brought it with them to
the laboratory on the clinical investigation days, at the previously
indicated time points. The total volume of the 24-h urine was
recorded, and aliquots were taken and frozen at −20◦C until
analysis. Individually estimated P intake (g/d) was calculated as
6.25 × 24-h urinary nitrogen (g/d) × 1.1, yielding PEst (30, 31).
Multiplication of urinary nitrogen by 1.1 was applied to correct
for nitrogen loss in feces (30, 31). When urea was measured,
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TABLE 2 EIEst and EIRep, reported macronutrient intakes, and reported GI and GL at baseline (week 0) and during the intervention in the HP and MP
groups1
Group Week 0 Week 26 Week 52 Week 104 Week 156
n (female/male) HP 923 (618/305) 644 (429/215) 528 (352/176) 450 (288/162) 413§ (271/142)
MP 899 (594/305) 648 (428/220) 551 (354/197) 439 (273/166) 420§ (271/149)
EIEst, MJ HP 12.3 ± 2.2 11.7 ± 2.0§ 11.7 ± 2.0§ 11.7 ± 1.9§ 11.6 ± 1.9§
MP 12.4 ± 2.2 11.7 ± 2.0§ 11.6 ± 2.0§ 11.7 ± 2.1§ 11.7 ± 2.0§
EIRep, MJ HP 8.8 ± 2.7 7.1 ± 1.9§,† 7.1 ± 2.2§,† 6.9 ± 2.1§ 6.8 ± 1.8§
MP 8.8 ± 2.7 6.8 ± 2.0§ 6.8 ± 2.0§ 6.7 ± 1.9§ 6.8 ± 2.1§
PEst, g HP 83.2 ± 33.1 92.7 ± 40.7§,† 97.8 ± 43.1§,† 88.1 ± 33.6§ 80.3 ± 30.8
MP 81.1 ± 33.4 83.3 ± 40.6 87.1 ± 37.1 82.5 ± 35.5 79.9 ± 31.3
PEst, En% HP 11.1 ± 4.1 13.0 ± 5.7§,† 13.5 ± 5.7§,† 12.0 ± 4.2§ 11.5 ± 4.4
MP 10.8 ± 4.2 11.5 ± 5.4 12.5 ± 5.7 11.1 ± 4.2 11.2 ± 4.3
PRep, g HP 93.2 ± 30.9 92.9 ± 26.4† 91.9 ± 29.1† 88.2 ± 28.2† 84.8 ± 26.6
MP 91.2 ± 30.2 76.0 ± 23.0§ 73.9 ± 21.3§ 74.3 ± 21.7§ 76.0 ± 25.8§
En% CHORep HP 41 ± 7 38 ± 7† 38 ± 7† 38 ± 8† 38 ± 8†
En% FRep HP 36 ± 7 33 ± 7 34 ± 7 34 ± 7 34 ± 7
En% PRep HP 18 ± 4 23 ± 5§,† 22 ± 6§,† 22 ± 5§,† 22 ± 5§,†
En% AlcRep HP 3 ± 5 3 ± 5 3 ± 4 3 ± 5 3 ± 5
En% CHORep MP 41 ± 8 44 ± 8 44 ± 8 43 ± 8 42 ± 8
En% FRep MP 37 ± 7 32 ± 7§ 33 ± 8 33 ± 7 34 ± 7
En% PRep MP 18 ± 4 19 ± 4 19 ± 4 19 ± 4 19 ± 4
En% AlcRep MP 3 ± 5 3 ± 4 3 ± 5 3 ± 4 3 ± 4
GI HP 56.3 ± 6.5 51.2 ± 7.8§,† 51.0 ± 8.7§,† 51.7 ± 8.6§,† 51.6 ± 9.6§,†
MP 56.5 ± 6.6 55.9 ± 8.0 54.8 ± 8.6 55.2 ± 8.6 54.9 ± 9.1
GL HP 119.3 ± 45.7 82.5 ± 33.0†,§ 82.8 ± 33.9§,† 81.4 ± 32.6§,† 79.7 ± 31.1§,†
MP 119.0 ± 45.0 98.7 ± 37.7 95.5 ± 37.1 94.3 ± 36.6 93.3 ± 35.8
1Values are means ± SDs. Linear mixed-model analyses adjusting for age, sex, study center, and BMI were used to assess differences between the
intervention groups. AlcRep, reported alcohol intake; CHORep, reported carbohydrate intake; EIEst, estimated energy intake; EIRep, reported energy intake;
En%, energy percentage; FRep, reported fat intake; GI, glycemic index; GL, glycemic load; HP, high-protein, low-GI diet; MP, moderate-protein, moderate-GI
diet; PEst, estimated protein intake; PRep, reported protein intake.
§Statistically significant difference from week 0 (P < 0.01).
†Significant difference between the intervention groups (P < 0.001).
8). Because P intake is more stable than CHO and fat (F) intake
between days, 24 h urinary nitrogen collection during 1 d may
be reasonably representative for P intake over that particular
period of time, including the days when the food intake diaries
were completed (30, 31). En% P intake was determined as En%
PEst = MJ estimated P intake/EIEst MJ × 100%, and similarly as
En% PRep = MJ reported P intake/EIRep MJ × 100%.
Four-day mean PRep was compared with PEst, yielding the ME
of PRep: [(PRep − PEst)/PEst] × 100%. The EI from CHO, F, and
alcohol together was estimated as nonprotein EIEst = EIEst − PEst.
The ME of the nonprotein EIRep or (CHORep + FRep + AlcRep)
= {[nonprotein EIEst − (CHORep + FRep + AlcRep)]/nonprotein
EIEst} × 100%, where AlcRep is reported alcohol intake.
Eating behavior
The Three Factor Eating Questionnaire (TFEQ) by Stunkard
and Messick (33) was provided to collect Factor 1 (F1) scores for
cognitive dietary restraint, indicating control regarding amount
of food consumed and food choice; Factor 2 (F2) scores
for disinhibition and emotional eating, indicating inhibition
of restraint and breaking the self-imposed diet, and eating as
consolidation for emotional life events; and Factor 3 (F3) scores
for general perception of hunger (33). The TFEQ consists
of 51 questions, i.e., 21 questions scoring on F1, 16 on F2, and
14 on F3, and was administered at each clinical investigation day
either on paper or electronically. It has been translated into and
validated in the relevant local languages, i.e., Danish, Finnish,
Dutch, Spanish, and Bulgarian (8). Its validity and reliability
have been reported for females and males, among weight groups,
in several countries, e.g., by Bohrer et al. (34). Regarding the
use of the TFEQ in studies on weight-loss maintenance, the
significance of the change and magnitude of scores on the TFEQ
lies in their role in explaining eating behavior in relation to weight
management. In healthy individuals, increased cognitive dietary
restraint (F1), together with decreased disinhibition, emotional
eating (F2), and hunger (F3), were associated with more favorable
weight maintenance (10–13, 34, 35).
Statistical analyses
For the analyses based on dietary intake during the complete
study of 36 mo, the data were pooled into 2 groups, yielding
the HP and the MP group, with both groups including the
same 2 PA arms. Statistical analyses were performed using the
Statistical Package for the Social Sciences version 23 (IBM SPSS
Statistics). Regarding the data distribution, skewness and kurtosis
were within acceptable ranges. Differences in BMI, body fat
percentage, HOMA-IR, HbA1c, TFEQ scores, and food intake
diary data between the 2 groups and changes over time were
assessed with linear mixed-model analysis. To answer the main
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PRep, PEst, EIRep, and EIEst with changes in HOMA-IR, HbA1c,
and BMI were assessed with linear mixed-model analyses.
Possible associations of changes in MEs, [(EIEst − EIRep)/EIEst]
× 100% and [(PRep − PEst)/PEst] × 100%, with changes in
HOMA-IR, HbA1c, BMI, and TFEQ scores were also assessed
with linear mixed-model analyses. Secondarily, associations with
age were investigated with linear mixed-model analyses. The
mixed-model analyses included the data from all participants
present at the particular time point, including those who dropped
out later. The linear mixed models included a participant-level
random intercept, a repeated subject-by-study center component,
and fixed effects for time, age, sex, and updated BMI at each
of the different time points, when applicable. Interaction terms
with time were removed from the model, if nonsignificant. The
subject-by-study center component accounted for differences,
e.g., in methods of measuring body composition. Results from
the mixed modeling analyses are presented as estimates and CIs.
Differences in MEs between groups and between sexes were
investigated separately, each with one-factor ANOVA.
Pearson’s correlation analyses were used to determine associ-
ations between EIRep and EIEst or between PEst and PRep.
Results
Characteristics of the participants
The present analyses included 1822 participants at week 0
which decreased to 833 at week 156, after excluding incomplete
4-d food intake diaries, urine collection, or accelerometry
(Figure 1). Anthropometric characteristics, HOMA-IR, HbA1c,
and TFEQ scores of the participants in the HP group and the
MP group did not differ statistically significantly from each
other at any time point (Table 1). Mixed-model analysis showed
statistically significant decreases from baseline in BMI, body
fat percentage, BMR, HOMA-IR, TFEQ-F2, and TFEQ-F3,
and at some time points for HbA1c (weeks 26 and 52), and
increases from baseline in TFEQ-F1 in both groups, without
differences between the HP and MP groups (Table 1). Moreover,
no differences were observed between study centers (data not
shown).
Changes in estimated and reported dietary intakes
Overall, EIEst and EIRep decreased significantly in both groups.
At weeks 26 and 52 EIRep was higher in the HP than in
the MP group (Table 2). Macronutrient compositions changed
differentially between groups. In the HP group, PEst (g or En%)
increased significantly from week 0 to week 104, whereas GI and
GL decreased from week 0 to week 156. Although in the HP
group there were no significant differences in En% reported for
F and CHO intake over time, whereas AlcRep was stable, together
(CHORep + FRep + AlcRep) decreased significantly over time,
from 80En% to 75En% (P < 0.01).
In the MP group En% PEst, PRep, GI, and GL did not
change significantly from week 0, whereas PRep (g) decreased
significantly, and En% FRep decreased significantly at week 26
(Table 2). PEst (En% and g) and PRep (g) were significantly higher
in the HP than in the MP group from week 26 to week 52; PRep
(g) was also higher in the HP than in the MP group at week 104
(Table 2). No differences were observed between study centers
(data not shown).
Comparison of reported with estimated EI and P intake
Overall, EIRep was positively associated with EIEst (r = 0.28;
P < 0.001) and PRep was positively associated with PEst (r = 0.26;
P < 0.001). Comparison of reported with estimated figures on
overall daily EI (EIRep compared with EIEst) and P intake (PRep
compared with PEst) resulted in a lower EIRep than EIEst and a
higher PRep than PEst. The difference between EIRep and EIEst
increased during the study, whereas the difference between PRep
and PEst was largest at weeks 0 and 156 (Figures 2, 3).
The mean ± SD ME of EIRep was 4.34 ± 2.54 MJ/d
or 1042.3 ± 259.2 kcal/d, or 37.8% ± 9.4%, representing
underreporting. The mean ± SD ME of EIRep, adjusted for the
relevant confounders, was larger in the MP than in the HP group
(4.49 ± 0.86 compared with 4.26 ± 0.79 MJ/d, or 1069.6 ± 204.0
compared with 1014.7 ± 187.5 kcal/d, or 38.8% ± 7.4%
compared with 36.8% ± 6.8%; P < 0.01), and larger in males
than in females (4.79 ± 1.1 compared with 4.18 ± 1.0 MJ/d
or 1141.5 ± 256.4 compared with 995.4 ± 239.9 kcal/d, or
41.4% ± 9.3% compared with 36.1% ± 8.7%; P < 0.01).
Associations of changes in the independent variables BMI,
HOMA-IR, and HbA1c with changes in the dependent variable
ME were expressed by an estimate that indicates the change in
the dependent variable associated with a 1-unit change in the
independent variable. For example: a change of 1 in BMI was
associated with a change of 0.619 MJ ME in EIRep (Table 3).
Overall, changes in BMI and TFEQ-F1 were positively,
whereas changes in TFEQ-F2 and TFEQ-F3 were inversely,
associated with changes in the ME of EIRep (Table 3). No
associations of changes in HOMA-IR or HbA1c with changes in
ME of EIRep were observed (Table 3). Age was not significantly
associated with change in ME of EIRep (estimate: 0.001; 95% CI:
−0.002, 0.004; P = 0.29).
The mean ± SD ME of PRep (g) was 26.7 ± 6.7 kcal, or
112 ± 27.9 kJ, or 13.5% ± 3.7%, representing overreporting.
The ME of PRep (g), adjusted for the relevant confounders, was
larger in the HP than in the MP group (30.0 ± 6.8 compared with
17.6 ± 3.8 kcal, or 126.1 ± 28.7 compared with 74.0 ± 15.9 kJ,
or 16.7% ± 3.8% compared with 9.8% ± 2.1%; P < 0.01),
and larger in females than in males (30.2 ± 7.01 compared with
11.3 ± 2.9 kcal, or 126.9 ± 29.5 compared with 47.6 ± 12.1 kJ,
or 16.8% ± 3.9% compared with 6.3% ± 1.6%; P < 0.01).
Age was significantly associated with a change in ME of PRep
(g/kg) (estimate: −0.190; 95% CI −0.368, −0.011; P = 0.026)
and with a change in ME of En% PRep (estimate: −0.394; 95%
CI: −0.786, −0.001; P = 0.026), indicating a smaller change in
ME with increasing age. Overall, change in BMI was inversely
associated with change in ME of PRep (g/kg). Changes in HOMA-
IR, HbA1c, or TFEQ-scores were not associated with changes
in ME of PRep (g/kg) (Table 3). Changes in BMI and in TFEQ-
F1 were positively, and changes in TFEQ-F2 and TFEQ-F3 were
inversely, associated with a change in ME of En% PRep (Table 3).
The ME of the remaining nonprotein reported dietary intake,
namely (CHORep + FRep + AlcRep), was 1118.4 ± 372.8 kcal/d,
or 4.66 ± 1.55 MJ/d, or 44.4% ± 14.8%. No differences in
underreporting EI and overreporting P intake were observed
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FIGURE 2 Mean reported minus estimated EI, P intake, and intake of CHO, F, and ethanol combined, as a percentage of estimated intake in the HP and
MP groups. Data are presented as means ± SDs. Linear mixed-model analyses adjusting for age, sex, study center, and BMI were used to assess differences
between the intervention groups. Significance levels of pairwise comparisons are indicated if the overall group effect was significant. ∗Significantly different
from MP group: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001. n (female/male), weeks 0, 26, 52, 104, and 156: HP: 923 (618/305); 644 (429/215); 528 (352/176);
450 (288/162); and 413 (271/142), respectively; MP: 899 (594/305); 648 (428/220); 551 (354/197); 439 (273/166); and 420 (271/149), respectively. CHO,
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FIGURE 3 Frequency distributions of reported minus estimated EI and P intake as percentages of estimated EI and P intake in both groups together, at the
different time points. n (female/male), weeks 0, 26, 52, 104, and 156: HP: 923 (618/305); 644 (429/215); 528 (352/176); 450 (288/162); and 413 (271/142),
respectively; MP: 899 (594/305); 648 (428/220); 551 (354/197); 439 (273/166); and 420 (271/149), respectively. EI, energy intake; P, protein.
Associations of changes in reported and estimated EI and P
intake with changes in HOMA-IR, HbA1c, and BMI
Because neither the changes in HOMA-IR, HbA1c, and BMI,
nor the associations of changes in EI or P intakes with changes in
HOMA-IR, HbA1c, and BMI differed between the groups, both
dietary groups were analyzed together. Because also PA or PA
intensity did not differ between the groups (4), all PREVIEW
study participants were analyzed together.
The magnitudes of possible associations, analyzed by mixed
modeling analyses, were expressed by an estimate indicating
the change in the dependent variable associated with a 1-
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TABLE 3 Associations of the dependent variables MEs of EIRep and PRep with the independent variables BMI, HOMA-IR, HbA1c, and TFEQ in the whole
group of participants1
Overall estimates
Variables (dependent, independent) Estimate 95% CI (Low, High) P
ME EIRep, MJ
BMI, kg/m2 0.619 0.493, 0.744 <0.001
HOMA-IR 0.001 −0.001, 0.003 0.14
HbA1c, mmol/mol 0.000 −0.001, 0.001 0.89
TFEQ F1 0.961 0.727, 1.196 <0.001
TFEQ F2 − 0.559 −0.731, −0.387 <0.001
TFEQ F3 − 0.733 −0.897, −0.569 <0.001
ME PRep, g/kg
BMI, kg/m2 − 0.220 −0.256, −0.185 0.03
HOMA-IR − 0.001 −0.002, 0.001 0.09
HbA1c, mmol/mol 0.001 −0.002, 0.003 0.66
TFEQ F1 − 0.651 −1.347, 0.045 0.06
TFEQ F2 0.000 −0.002, 0.003 0.71
TFEQ F3 0.002 −0.001, 0.005 0.20
ME PRep, En%
BMI, kg/m2 2.177 1.458, 2.896 <0.001
HOMA-IR 0.503 −2.049, 3.055 0.20
HbA1c, mmol/mol 0.002 −0.002, 0.006 0.32
TFEQ F1 1.642 0.074, 2.548 <0.001
TFEQ F2 − 3.550 −4.604, −2.496 <0.001
TFEQ F3 − 2.942 −3.861, −2.024 <0.001
1Linear mixed models including a participant-level random intercept, a repeated subject-by-study center component, and fixed effects for time, age, sex,
and BMI when applicable were used to assess associations of MEs of EIRep and PRep with BMI, HOMA-IR, and HbA1c. ME of EIRep: (EIEst −
EIRep)/EIEst × 100%; ME of PRep: (PRep − PEst)/PEst × 100%. Interaction terms with time were removed from the model, if nonsignificant. P < 0.05
indicates statistical significance. The estimates indicate the changes in the dependent variable associated with a 1-unit change of the independent variables.
Example: a change of 1 kg/m2 in BMI is associated with a change of 0.619 MJ ME in EIRep. EIEst, estimated energy intake; EIRep, reported energy intake;
En%, energy percentage; F1, Factor 1 (cognitive dietary restraint); F2, Factor 2 (disinhibition); F3, Factor 3 (hunger); HbA1c, glycated hemoglobin; ME,
measurement error; PEst, estimated protein intake; PRep, reported protein intake; TFEQ, Three Factor Eating Questionnaire.
change in EIEst was associated with a change of 1.15 in BMI
(Table 4).
Overall, changes in EIEst and EIRep were positively associated
with changes in BMI corrected for age, sex, and study center
(Table 4). Changes in EIEst and EIRep were not independently
associated with changes in HOMA-IR or HbA1c, corrected for
age, sex, study center, and BMI (Table 4). Change in En% PEst
was not independently associated with changes in HOMA-IR or
HbA1c, whereas a trend appeared for the association with change
in BMI (P = 0.05). Change in En% PRep was not associated with
changes in HOMA-IR and HbA1c, yet it was inversely associated
with change in BMI (Table 4).
Discussion
The present study investigated if changes in PEst, PRep EIEst,
and EIRep, during a 3-y lifestyle intervention focused on weight-
loss maintenance and reduction of HOMA-IR, were associated
with changes in HOMA-IR, HbA1c, and BMI, in a pooled post
hoc analysis of all eligible participants.
Overall, increases in PEst and PRep (g/kg) were associated with
decreases in HbA1c and BMI, but not with a decrease in HOMA-
IR. Increases in En% PEst and En% PRep were not associated with
decreases in HOMA-IR and HbA1c. The increase in En% PEst
was only a trend, but the increase in En% PRep was associated
with a decrease in BMI. Decreases in EIEst and EIRep were
not independently associated with decreases in HOMA-IR and
HbA1c. Self-evidently, decreases in EIEst and EIRep were associ-
ated with a decrease in BMI (4, 32). Although the PREVIEW
study showed that the decrease in HOMA-IR was associated
with the decrease in BMI (4), the decrease in EIEst and increase
in PEst were not independently associated with the decrease in
HOMA-IR.
Associations of increase in P intake with decreases in HOMA-
IR and HbA1c are inconclusive in the literature. This may
depend on the P range and source (plant or meat) and the
body-weight status of the participant (15–20, 41). The presently
observed association with a decrease in HbA1c is in line with
the Lifelines study (16) considering the increase in P intake,
but we did not distinguish plant and animal P. The food
tables we used did not enable us to discriminate between P
sources, which is a limitation to the present analyses. An inverse
association between HOMA-IR and P intake usually is explained
by the glycemia-lowering effect of P intake, or by reduced
insulinotropic properties, or by weight loss in participants with
overweight (17–20). In the latter, HOMA-IR is associated with
elevated plasma branched-chain amino acids that decrease during
weight loss (20), which may explain the weight loss–induced
increase in insulin sensitivity. In healthy subjects, a high-protein
diet appeared to increase HOMA-IR in part through elevated
plasma amino acid concentrations, inhibiting muscle glucose
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TABLE 4 Associations of changes in the independent variables EIEst, EIRep, PEst, and PRep with changes in the dependent variables BMI, HOMA-IR, and
HbA1c in the whole group of participants1
Overall estimates
Variables (independent, dependent) Estimate 95% CI (Low, High) P
EIEst, MJ/d
BMI, kg/m2 1.150 1.088, 1.227 <0.001
HOMA-IR 0.197 −0.002, 3.967 0.15
HbA1c, mmol/mol − 0.051 −0.109, 0.010 0.07
EIRep, MJ/d
BMI, kg/m2 0.114 0.074, 0.153 <0.001
HOMA-IR 0.010 −0.005, 0.026 0.09
HbA1c, mmol/mol − 0.012 −0.038, 0.014 0.17
PEst, g/kg
BMI, kg/m2 − 0.930 −1.230, −0.630 <0.001
HOMA-IR 0.002 −0.005, 0.080 0.80
HbA1c, mmol/mol − 0.400 −0.730, −0.080 0.02
PRep, g/kg
BMI, kg/m2 − 1.300 −1.660, −0.950 <0.001
HOMA-IR 0.029 −0.080, 0.138 0.23
HbA1c, mmol/mol − 0.410 −0.770, −0.090 0.01
PEst, En%
BMI, kg/m2 − 0.002 −0.009, 0.005 0.05
HOMA-IR − 0.006 −0.015, 0.003 0.16
HbA1c, mmol/mol − 0.012 −0.038, 0.014 0.26
PRep, En%
BMI, kg/m2 − 0.011 −0.020, −0.002 0.02
HOMA-IR − 0.007 −0.014, 0.001 0.07
HbA1c, mmol/mol − 0.016 −0.024, 0.001 0.06
1Linear mixed models including a participant-level random intercept, a repeated subject-by-study center component, and fixed effects for time, age, sex,
and BMI when applicable were used to assess associations of changes in EIRep and EIEst, PRep and PEst (g/kg), and PRep and PEst (En%) with changes in BMI,
HOMA-IR, and HbA1c. Interaction terms with time were removed from the model, if nonsignificant. P < 0.05 indicates statistical significance. Estimates
indicate the change in the dependent variable with a 1-unit change in the independent variable. For example: 1 MJ/d change in EIEst is associated with a
change of 1.15 kg/m2 in BMI. EIEst, estimated energy intake; EIRep, reported energy intake; En%, energy percentage; HbA1c, glycated hemoglobin; PEst,
estimated protein intake; PRep, reported protein intake.
The observation of increases in PEst and PRep (g/kg and En%)
being associated with a decrease in BMI is in line with previous
observations, and has been explained by dietary P inducing
sustained satiety, energy expenditure, and sparing body FFM
despite weight reduction, thus preventing weight cycling (10–
15). However, the decrease in BMI may be associated with not
only the observed increases in PEst and PRep, but also the decrease
in nonprotein intake. Owing to the lack of biomarkers, we were
not able to distinguish the individual contributions of the other
macronutrients (21, 42). A previous study, uncoupling high P
and low CHO intake, showed that weight-loss maintenance was
primarily due to an increase in dietary P, and not to a reduction
of CHO intake (12).
The observed lack of significant independent associations of
increases in En% PEst and En% PRep, and decreases in EIEst and
EIRep, with decreases in HOMA-IR and HbA1c may partly be
due to taking changes in BMI into account, by including updated
BMI at each time point as a fixed-effect level in the mixed-model
analyses. In addition, En% PEst and En% PRep were corrected for
EIEst and EIRep, showing that associations with changes in En%
P were largely affected by changes in EI. The association of an
increase in En% PRep but only an increase in En% PEst as a trend
with a decrease in BMI may be due to the ME of En% PRep being
affected by the ME of EIRep.
The observed ME of EIRep and its association with BMI,
and of PRep (g/kg), mainly at the start and at the end of the
study, confirm earlier observations (21–29, 42), yet now they
have been observed over a longer period of time. The ME of the
nonprotein intake is in line with a previous study that reported that
especially underreported F intake contributes to underreported
EIRep. Reported dietary intakes in the HP and MP groups were
in line with the dietary instructions. The lower ME of EI in the
HP than in the MP group may be explained by the higher PRep in
the HP group. As observed previously, TFEQ-F1 was increased
whereas TFEQ-F2 and TFEQ-F3 were decreased during weight-
loss maintenance, indicating a positive attitude toward dieting
(10–14, 34, 35). Changes in BMI and TFEQ-F1 were positively
associated with a change in ME of EI, whereas changes in TFEQ-
F2 and TFEQ-F3 were inversely associated with a change in ME
of EI, implying that a positive attitude toward dieting is associated
with an increase in ME.
The clinical relevance of the present study lies in showing
that a moderate increase in P intake and decrease in EI were
independently associated with moderate decreases in HbA1c and
BMI over 36 mo, whereas the main PREVIEW study showed that
a reduction in BMI was associated with a reduction in HOMA-
IR (4). This may contribute to reducing the incidence of T2D in
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on potential dietary strategies for T2D prevention. However, the
larger En% PRep than PEst, the association between PRep and PEst,
and the larger estimate with PRep than with PEst of associations
with changes in BMI suggest that higher En% PEst would be
necessary, achieved by a higher PEst (g/kg) and a considerably
lower EIEst, in order to establish stronger associations with
reductions in BMI (10, 13–15) and concurrently in HOMA-IR.
Given the range in characteristics of the participants regarding
age, sex, and environment including geography, the outcomes
are generalizable for individuals with overweight, obesity,
postobesity, and with present or previous prediabetes.
Our estimates of EIs have strengths and limitations. Doubly
labeled water–measured energy expenditure at each time point
is the gold standard for estimating EI when participants are in
energy balance and weight stable (42). However, this approach
was not applied in the present study. Instead, we actually
measured changes in body composition at each time point in order
to calculate BMR, as well as changes in PA at each time point
to calculate PAL, which is a strength of the present approach
(29, 32, 42). The estimated BMR was in line with the observed
BMR during a respiratory chamber study in a representative
sample of the participants by the end of the intervention (43).
The translation of counts to PAL was based upon the studies
by Ekelund et al. (39) and Freedson et al. (40) yielding similar
outcomes. The outcome of a PAL of ∼1.6 is in line with our
previous studies on weight maintenance after weight loss in
participants with overweight or obesity (10, 11). The estimate
of EI being equal to EE is based upon the assumption of energy
balance at the time points of measuring. However, the participants
were regaining body weight from week 26 onwards (4). Their
6% weight regain (∼6.1 kg) over 130 wk after 11% weight
loss (∼11.2 kg at week 26) (4) was equivalent to a positive
energy balance of 6.1 kg × 30 MJ/kg = 183 MJ over 130 wk
or 910 d (32), resulting in 183/910 = 201.10 kJ/d. This is within
the margin of error of energy balance estimation (32). Further
strengths of this study are the longitudinal design, encompassing
a large number of participants from 8 different study centers;
comprehensive measures of anthropometry, insulin resistance,
dietary intake, and PA; and use of biomarkers, not only to confirm
differences but mainly to calculate relevant results. A limitation
of the present study is that it was designed as an RCT but
analyzed as an observational study. A successful RCT design
with full compliance would have allowed us to attribute any
observed effects to the treatments being compared. The present
observational analyses imply that outcomes may be caused by
differences between the participants, as is indicated by, e.g., the
scores on the TFEQ.
In conclusion, during weight-loss maintenance in adults with
prediabetes, an increase in P intake and decrease in EI were
not associated with a decrease in HOMA-IR beyond their
associations with a decrease in BMI; increases in PEst and PRep
(g/kg) were associated with a decrease in HbA1c. PRep and EIRep
showed larger changes and stronger associations than PEst and
EIEst.
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